Title of the cohort
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study
Acronym for cohort
ATBC Study
Name of Principal Investigator
| Title | Research professor, MD, Ph.D |
| First name | Jarmo |
| Last name | Virtamo |
Address of institution where award is held
| Institution | The National Institute for Health and Welfare |
| Street Address | Mannerheimintie 166 |
| City | Helsinki |
| Postcode | 00330 |
Country
- Finland
Website
http://atbcstudy.cancer.gov
Contact email
Funding source
1. The cohort includes, or expects to include, incidence of the following conditions
- Neurodegenerative disease in general
When studies on the above condition(s) are expected to become possible
- Already possible
2a. Stated aim of the cohort
ATBC Study was a randomized, double-blind, placebo-controlled, primary prevention trial to determine whether daily supplementation with alpha-tocopherol, beta-carotene, or both would reduce the incidence of lung or other cancers among male smokers.
2b. Features distinguishing this cohort from other population cohorts
3a. i) Number of publications that involve use of cohort to date
304
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)
http://atbcstudy.cancer.gov/publications/search/index.pl
4a. Study criteria: age range of participants at recruitment
| Age in years from: | 50 |
| To (‘until death’ if applicable): | 69 |
4b. Study criteria: inclusion criteria
Men of 50-69 years old smoking 5 or more cigarettes a day
4c. Study criteria: exclusion criteria
Men who had prior cancer or serious illness or who reported current use of vitamins E (>20 mg/day), A (>20,000 IU/day), or beta-carotene (>6 mg/day) were ineligible.
5. Size of the cohort (i.e. number of participants enrolled)
- More than 15,000
6a. Measures used to characterise participants
?
6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
- No
7. Study design
- Longitudinal
8. Cases matched by
- Other health assessment (specify) / N/A
- no neurodegenerative case-control definition
9a. Does the study include a specialised subset of control participants
- No
9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date
01-01-1985
10a. ii) Data collection end date
30-04-1993
10a iii) Data collection for this study is
- Data analysis ongoing
- Closed to new patients
10b. Plans to continue the cohort study beyond the current projected end date
- No
11. Data collected
- Through links to other records or registers (such as dental records, police records etc). Please specify
- Finnish cancer registry, morbidity registry
12. System in place to enable re-contact with patients for future studies
13a. Format and availability of data stored in a database
Language used:
13b. Format and availability of data held as individual records
Language used:
14a. Are data available to other groups
Yes
14b. Access policy/mechanisms for access if data are available to other groups
- Apply to PI or co-ordinator at resource
- Access Committee mechanism
- National access
- International access
- Resource has own ethics approval so usually no need for separate external ethics approval
15. Data sharing policy specified as a condition of use
- Data made publicly available after a specified time point
16a. Are tissues/samples/DNA available to other groups
Yes
16b. i) Description of available tissues/samples/DNA
- Living donors: DNA
16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
Yes
17. Is information on biological characteristics available to other groups
- No